SC 13G: ARROWHEAD PHARMACEUTICALS, INC.

AI Summary

SC 13G filing by ARROWHEAD PHARMACEUTICALS, INC..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• p24-3166sc13g.htm (SC 13G) — 56KB
• p24-3166exhibit99_1.htm (EX-1) — 3KB
• 0000902664-24-006530.txt ( ) — 61KB

(a)

Item 1(a). NAME OF ISSUER Arrowhead Pharmaceuticals, Inc. (the " Issuer ")

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES 177 E. Colorado Blvd, Suite 700 Pasadena, CA 91105

(a)

Item 2(a). NAME OF PERSON FILING This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company (" Avoro "), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh (" Dr. Aghazadeh ," and together with Avoro, the " Reporting Persons "), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.

(c)

Item 2(c). CITIZENSHIP Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES Common Stock, par value $0.001 per share (the " Common Stock ")

(e)

Item 2(e). CUSIP NUMBER 04280A100 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act; (b) ¨ Bank as defined in Section 3(a)(6) of the Act; (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act; CUSIP No. 04280A100 13G Page 5 of 7 Pages (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940; (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:_______________________________________ Item 4. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference. The percentage set forth in Row 11 of this Schedule 13G is calculated based upon 124,315,274 shares of Common Stock outstanding as of August 1, 2024, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024. Item 5. Not applicable. Item 6. See Item 2. Avoro Life Sciences Fund LLC has the right to receive or the power to di

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: November 14, 2024 AVORO CAPITAL ADVISORS LLC /s/ Scott Epstein Name: Scott Epstein Title: Chief Financial Officer & Chief Compliance Officer /s/ Behzad Aghazadeh BEHZAD AGHAZADEH

View Full Filing

View this SC 13G filing on SEC EDGAR